Profit Margin (Quarterly) Chart

View Profit Margin (Quarterly) for BMY.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Profit Margin (Quarterly) Chart
Start Trial

Historical Profit Margin (Quarterly) Data

View and export this data back to 1996. Start Trial.
Date Value
June 30, 2026 25.54%
March 31, 2026 23.31%
December 31, 2025 8.69%
September 30, 2025 17.96%
June 30, 2025 10.70%
March 31, 2025 21.98%
December 31, 2024 0.62%
September 30, 2024 10.22%
June 30, 2024 13.80%
March 31, 2024 -100.4%
December 31, 2023 15.35%
September 30, 2023 17.64%
June 30, 2023 18.50%
March 31, 2023 20.00%
December 31, 2022 17.75%
September 30, 2022 14.33%
June 30, 2022 12.02%
March 31, 2022 11.01%
December 31, 2021 19.79%
September 30, 2021 13.35%
June 30, 2021 9.07%
March 31, 2021 18.32%
December 31, 2020 -90.59%
September 30, 2020 17.82%
June 30, 2020 -0.79%
Date Value
March 31, 2020 -7.11%
December 31, 2019 -13.34%
September 30, 2019 22.74%
June 30, 2019 22.94%
March 31, 2019 28.97%
December 31, 2018 19.92%
September 30, 2018 33.60%
June 30, 2018 6.70%
March 31, 2018 28.79%
December 31, 2017 -42.74%
September 30, 2017 16.29%
June 30, 2017 17.92%
March 31, 2017 30.96%
December 31, 2016 17.13%
September 30, 2016 24.69%
June 30, 2016 24.39%
March 31, 2016 27.47%
December 31, 2015 -3.01%
September 30, 2015 17.94%
June 30, 2015 -2.64%
March 31, 2015 29.67%
December 31, 2014 0.63%
September 30, 2014 18.67%
June 30, 2014 8.59%
March 31, 2014 24.56%

Profit Margin Definition

Profit Margin is calculated using Net Income/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into profit. An analyst looking at profit margin might look for a higher profit margin relative to other comparable companies as well as a profit margin that is growing.

Read full definition.

Profit Margin (Quarterly) Range, Past 5 Years

View Profit Margin (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Profit Margin (Quarterly) Benchmarks

View Profit Margin (Quarterly) Benchmarks
Start Trial
Johnson & Johnson 21.86%
Eli Lilly & Co. 30.88%
Merck & Co., Inc. -8.06%
Pfizer Inc. -1.64%
AstraZeneca PLC 20.15%